Adverum Biotechnologies, Inc.Viés de alta
time to add target 2.25
time to add target 2.25 stoploss 1.13..Adverum is moving forward with its eye disease gene therapy that caused headaches in April 2021, but is doing so with fewer staff on board.
The biotech is laying off 78 employees, or about 38% of its workforce, in order to conserve cash and keep the lights on into 2025, according to an SEC filing.
The biotech is laying off 78 employees, or about 38% of its workforce, in order to conserve cash and keep the lights on into 2025, according to an SEC filing.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.